Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy

T. Yanagisawa, K. Hata, S. Narita, S. Hatakeyama, K. Mori, Y. Yata, T. Sano, T. Otsuka, S. Hara, K. Miyajima, Y. Enei, W. Fukuokaya, M. Nakazono, A. Matsukawa, J. Miki, T. Habuchi, C. Ohyama, SF. Shariat, T. Kimura

. 2023 ; 83 (6) : 563-571. [pub] 20230120

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003609

PURPOSE: We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real-world clinical practice setting. METHODS: The records of 336 patients who harbored de novo high-risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC (n = 109) or ABI (n = 227) were retrospectively analyzed. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), time to 2nd-line progression (PFS2), and 2nd- and 3rd-line PFS, were compared. We used one-to-two propensity score matching to minimize the confounders. The differential efficacy of 2nd-line therapy based on agents in each arm was evaluated using the unmatched cohort as an additional interest. RESULTS: After propensity score matching, 86 patients treated with DOC + ADT and 172 with ABI + ADT were available for analyses. The 3-year OS and CSS for DOC versus ABI were 76.2% versus 75.1% (p = 0.8) and 78.2% versus 78.6% (p = 1), respectively. There was no difference in the median PFS2 (49 vs. 43 months, p = 0.39), while the median time to CRPC in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). The median 2nd-line PFS (14 vs. 4 months, p < 0.001) and 3rd-line PFS (4 vs. 2 months, p = 0.012) were significantly better in the DOC group than in the ABI group. Among the unmatched cohort, after ABI for mHSPC, the median 2nd-line PFS did not differ between the patients treated with DOC and those treated with enzalutamide as 2nd-line therapy (both 3 months, p = 0.8). CONCLUSIONS: ADT with DOC or ABI has comparable oncologic outcomes in terms of OS, CSS, and PFS2 in patients with de novo high-risk mHSPC. Compared to DOC, ABI resulted in longer time to CRPC but worse 2nd and 3rd-line PFS. Further studies are needed to clarify the optimal sequence of therapy in the upfront intensive treatment era.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003609
003      
CZ-PrNML
005      
20230425140743.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.24488 $2 doi
035    __
$a (PubMed)36661102
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Yanagisawa, Takafumi $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000274100712
245    10
$a Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy / $c T. Yanagisawa, K. Hata, S. Narita, S. Hatakeyama, K. Mori, Y. Yata, T. Sano, T. Otsuka, S. Hara, K. Miyajima, Y. Enei, W. Fukuokaya, M. Nakazono, A. Matsukawa, J. Miki, T. Habuchi, C. Ohyama, SF. Shariat, T. Kimura
520    9_
$a PURPOSE: We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real-world clinical practice setting. METHODS: The records of 336 patients who harbored de novo high-risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC (n = 109) or ABI (n = 227) were retrospectively analyzed. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), time to 2nd-line progression (PFS2), and 2nd- and 3rd-line PFS, were compared. We used one-to-two propensity score matching to minimize the confounders. The differential efficacy of 2nd-line therapy based on agents in each arm was evaluated using the unmatched cohort as an additional interest. RESULTS: After propensity score matching, 86 patients treated with DOC + ADT and 172 with ABI + ADT were available for analyses. The 3-year OS and CSS for DOC versus ABI were 76.2% versus 75.1% (p = 0.8) and 78.2% versus 78.6% (p = 1), respectively. There was no difference in the median PFS2 (49 vs. 43 months, p = 0.39), while the median time to CRPC in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). The median 2nd-line PFS (14 vs. 4 months, p < 0.001) and 3rd-line PFS (4 vs. 2 months, p = 0.012) were significantly better in the DOC group than in the ABI group. Among the unmatched cohort, after ABI for mHSPC, the median 2nd-line PFS did not differ between the patients treated with DOC and those treated with enzalutamide as 2nd-line therapy (both 3 months, p = 0.8). CONCLUSIONS: ADT with DOC or ABI has comparable oncologic outcomes in terms of OS, CSS, and PFS2 in patients with de novo high-risk mHSPC. Compared to DOC, ABI resulted in longer time to CRPC but worse 2nd and 3rd-line PFS. Further studies are needed to clarify the optimal sequence of therapy in the upfront intensive treatment era.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a docetaxel $x terapeutické užití $7 D000077143
650    12
$a nádory prostaty $x patologie $7 D011471
650    12
$a nádory prostaty rezistentní na kastraci $x patologie $7 D064129
650    _2
$a antagonisté androgenů $x terapeutické užití $7 D000726
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a hormony $x terapeutické užití $7 D006728
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hata, Kenichi $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $u Department of Urology, Atsugi City Hospital, Kanagawa, Japan
700    1_
$a Narita, Shintaro $u Department of Urology, Akita University School of Medicine, Akita, Japan
700    1_
$a Hatakeyama, Shingo $u Department of Urology, Division of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Aomori, Japan
700    1_
$a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Yata, Yuji $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Sano, Takayuki $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Otsuka, Takashi $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Hara, Shuhei $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Miyajima, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Enei, Yuki $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Fukuokaya, Wataru $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/000000031044912X
700    1_
$a Nakazono, Minoru $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Matsukawa, Akihiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Miki, Jun $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000246388640
700    1_
$a Habuchi, Tomonori $u Department of Urology, Akita University School of Medicine, Akita, Japan
700    1_
$a Ohyama, Chikara $u Department of Urology, Division of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Aomori, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 83, č. 6 (2023), s. 563-571
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36661102 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140740 $b ABA008
999    __
$a ok $b bmc $g 1924343 $s 1189818
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 83 $c 6 $d 563-571 $e 20230120 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace